{
"id":"mk19_b_hm_q044",
"number":44,
"bookId":"hm",
"correctAnswer":"E",
"title":"Question 44",
"stimulus":[
{
"type":"p",
"hlId":"74bb7e",
"children":[
"A 70-year-old man is evaluated for recently discovered erythrocytosis. Other than daytime sleepiness, he feels well. He has a 50 pack-year history of smoking and continues to smoke. He also has obesity, hypertension, and obstructive sleep apnea. He is nonadherent with continuous positive airway pressure (CPAP) ventilation because of discomfort. His only medication is lisinopril."
]
},
{
"type":"p",
"hlId":"196ea9",
"children":[
"On physical examination, vital signs are normal. BMI is 35. ",
{
"type":"reference-range-link",
"referenceRange":"Blood gases, Oxygen saturation, arterial (ambient air)",
"children":[
"Oxygen saturation"
]
},
" is 98% breathing ambient air. The examination is unremarkable."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"51169d",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Erythropoietin",
"children":[
"Erythropoietin"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"e92836",
"class":"cell text l",
"children":[
"33 mU/mL (33 U/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f1fae6",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Hematocrit",
"children":[
"Hematocrit"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"3ee2d7",
"class":"cell text l",
"children":[
"52%"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"2989c0",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Leukocyte count",
"children":[
"Leukocyte count"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"fd777f",
"class":"cell text l",
"children":[
"8000/μL (8 × 10",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"9"
]
},
"/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"fcac73",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Platelet count",
"children":[
"Platelet count"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"dc9a4f",
"class":"cell text l",
"children":[
"185,000/μL (185 × 10",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"9"
]
},
"/L)"
]
}
]
}
]
}
]
}
]
},
{
"type":"p",
"hlId":"d7edae",
"children":[
"Genetic testing is negative for the ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"JAK2"
]
},
" V617F mutation."
]
},
{
"type":"p",
"hlId":"925924",
"children":[
"He receives brief behavioral intervention for smoking cessation and is offered varenicline. He is referred to sleep medicine to discuss strategies to decrease discomfort with CPAP and to improve adherence."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"1e31fb",
"children":[
"Which of the following is the most appropriate additional management?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Bone marrow biopsy"
}
},
{
"letter":"B",
"text":{
"__html":"Hydroxyurea"
}
},
{
"letter":"C",
"text":{
"__html":"Phlebotomy"
}
},
{
"letter":"D",
"text":{
"__html":"Ruxolitinib"
}
},
{
"letter":"E",
"text":{
"__html":"No further testing or interventions"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"dbed55",
"hvc":true,
"children":[
"Secondary causes of erythrocytosis arise through chronic or intermittent hypoxia, and correcting these underlying causes (e.g., cigarette smoking, obstructive sleep apnea) is the first step in management."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"90ba1b",
"children":[
"Besides smoking cessation and adherence to continuous positive airway pressure (CPAP) ventilation, no further management is needed at this time (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option E"
]
},
"). This patient has erythrocytosis, likely resulting from smoking and obstructive sleep apnea. His erythropoietin level is high normal, and he is negative for the ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"JAK2"
]
},
" V617F mutation, which strongly indicates a secondary cause of erythrocytosis. Primary polycythemia vera (PV) is often characterized by an elevated erythrocyte mass and a low erythropoietin level, and approximately 95% of patients have the ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"JAK2"
]
},
" mutation, resulting in overproduction of erythrocytes, granulocytes, and platelets. Secondary erythrocytosis is more common, with hypoxia-induced reactive increases in erythrocyte production often being the underlying cause. This is seen with conditions such as COPD and sleep disordered breathing such as obstructive sleep apnea. Carbon monoxide exposure and chronic hypoxia associated with cigarette smoking are also secondary causes of erythrocytosis. This patient should stop smoking, overcome obstacles for use of CPAP ventilation, and continue to be monitored."
]
},
{
"type":"p",
"hlId":"159443",
"children":[
"Bone marrow biopsy is rarely indicated in evaluating erythrocytosis (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
"). The bone marrow in patients with PV will typically show hypercellularity with an increase in megakaryocytes and erythroid and myeloid precursors; the marrow may also reveal increased fibrosis. Even if PV is suspected, diagnosis is usually confirmed without the need of bone marrow evaluation. In secondary erythrocytosis, the marrow will show a reactive increase in erythroid precursors but will not be helpful in establishing the cause."
]
},
{
"type":"p",
"hlId":"a4b9b3",
"children":[
"Hydroxyurea and ruxolitinib are treatment options for primary PV but are not indicated for secondary erythrocytosis (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Options B, D"
]
},
")."
]
},
{
"type":"p",
"hlId":"7179f2",
"children":[
"The ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"JAK2"
]
},
" mutation seen in primary PV is associated with an increased risk for thrombotic events, and studies have shown that maintaining a hematocrit less than 45% reduces the risk for adverse cardiovascular and thrombotic events. Because the increase in erythrocyte mass in secondary erythrocytosis is a compensatory response to tissue hypoxia, reducing the number of erythrocytes through phlebotomy may worsen outcomes (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
"). Phlebotomy in reactive situations is considered on a case-by-case basis and is often limited to patients with extreme hematocrit elevations (>54%) and who have symptoms attributable to hyperviscosity."
]
}
],
"relatedSection":"mk19_b_hm_s2_3_2",
"objective":{
"__html":"Manage secondary causes of erythrocytosis."
},
"references":[
[
"Rumi E, Cazzola M. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. Blood. 2017;129:680-692. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/28028026",
"target":"_blank"
},
"children":[
"PMID: 28028026"
]
},
" doi:10.1182/blood-2016-10-695957"
]
],
"hospitalist":false,
"hvc":true,
"peerComparison":{
"A":1,
"B":6,
"C":14,
"D":1,
"E":78
},
"hlIds":[
"74bb7e",
"196ea9",
"a462a3",
"51169d",
"e92836",
"f1fae6",
"3ee2d7",
"2989c0",
"fd777f",
"fcac73",
"dc9a4f",
"d7edae",
"925924",
"1e31fb",
"dbed55",
"90ba1b",
"159443",
"a4b9b3",
"7179f2"
]
}